RxDoctor Payments Data

Joaquina Baranda, MD

Medical Oncology · Westwood, KSNPI 1801989041

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $13,109 of the $17,639 with a category attached, or 74.3%. Sanofi-aventis U.S. LLC accounts for 76.3% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $13,489 and has fallen 99.3% since, to $94 in 2023.

$17,639in general payments, 2019–2025

Across 14 payments — averaging $1259.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$13K
  • Pfizer$4K
  • Genentech, Inc.$238
  • Johnson & Johnson$119
  • Merck$94
  • Novartis$22
$2,673,176in research payments, 2019–2025

Across 354 payments — averaging $7551.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$1.1M
  • Exelixis Inc.$647K
  • Astellas Pharma Global Development$390K
  • Pfizer$226K
  • AstraZeneca$110K
  • Incyte Corporation$107K
  • plus $114K from 6 others

What the payments were for

  • Speaking & faculty fees$3,70021%
  • Travel & lodging$13,10974%
  • Food & beverage$8315%

General payments by program year

19
20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi-aventis U.S. LLC8$13,466
Pfizer1$3,700
Genentech, Inc.2$238
Johnson & Johnson1$119
Merck1$94
Novartis1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,639 in reported general payments places this provider in the 65th percentile of 25 medical oncology providers in Kansas.

See all medical oncology providers in Kansas

Medicare billing

Part B allowed, 2024
$9,479
Medicare patients
37
Services billed
130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Westwood

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →